Invivyd, Inc. Director Sells $30,718 in Stock

On December 16th, 2023, Terrance Mcguire, a Director at Invivyd, Inc. (NASDAQ:IVVD), sold 65,359 shares of the company's stock. The shares were sold at an average price of $0.47, leading to a total value of $30,718.73 from the transaction. Following this sale, Mcguire's direct ownership in the company is now 4,012,320 shares, which is valued at approximately $1,885,790.40. This sale represents a decrease of 1.60% in his ownership position. Details of the transaction were disclosed in a filing with the Securities and Exchange Commission.

Recently, Mcguire has completed several other trades as well:

• On December 11th, he sold 160,400 shares at an average price of $0.59, totaling $94,636.00.
• On December 9th, he sold 150,000 shares at an average price of $0.61, totaling $91,500.00.

Invivyd Stock Performance

As of the last trading session, IVVD stock decreased by 17.6%, closing at $0.45. The trading volume was 1,228,420 shares, significantly higher than the average volume of 651,886 shares. The company has a 50-day moving average price of $0.82 and a 200-day moving average price of $1.05. Invivyd has a market capitalization of $53.89 million, a P/E ratio of -0.23, and a beta value of 0.53. Over the past year, the stock has seen a low of $0.45 and a high of $5.20.

Analyst Ratings and Price Targets

Several research firms have recently updated their price targets for Invivyd. On November 20th, Morgan Stanley decreased its target price from $9.50 to $3.55 while maintaining an "overweight" rating. HC Wainwright also lowered its price objective from $15.00 to $10.00, designating it as a "buy." EF Hutton Acquisition Co. I upgraded Invivyd to a "strong-buy" rating on October 30th. Additionally, D. Boral Capital reiterated a "buy" rating and set a target price of $9.00. Currently, four analysts recommend the stock as a buy, while one has given it a strong buy rating. According to MarketBeat, the consensus rating for Invivyd is "Buy" with an average target price of $7.89.

Institutional Investors' Involvement

Recent activities among institutional investors indicate increased interest in Invivyd. State Street Corp increased its stake by 3.7% during the third quarter, now owning 1,018,640 shares valued at approximately $1,039,000 after buying an additional 35,904 shares. Marshall Wace LLP grew its position by 4.2% during the second quarter, resulting in ownership of 786,899 shares worth around $866,000. Acadian Asset Management LLC significantly increased its stake by 232.0%, owning 678,706 shares valued at $745,000 after acquiring 474,301 additional shares. Other institutions such as Duquesne Family Office LLC and Renaissance Technologies LLC also participated in buying shares. Overall, institutional investors hold 70.36% of the company's stock.

About Invivyd, Inc.

Invivyd, Inc. is a biopharmaceutical company focused on developing antibody-based treatments for infectious diseases in the United States. The company has developed a platform called INVYMAB, integrating viral surveillance and predictive modeling with advanced antibody engineering.

stocks, finance, investors